Effect of Angelica Buxue Decoction on patients with early lung cancer after resection
SHI Shengyu1 WANG Xuwen1 ZHAO Liangwei2 DU Yanqing1 JIANG Ming3 LIU Chongbin4
1.Department of General Surgery, Huzhou Traditional Chinese Medicine Hospital Affiliated to Zhejiang Chinese Medical University, Zhejiang Province, Huzhou 313000, China; 2.Department of Urology, Huzhou Traditional Chinese Medicine Hospital Affiliated to Zhejiang Chinese Medical University, Zhejiang Province, Huzhou 313000, China; 3.Department of Anesthesiology, Huzhou Traditional Chinese Medicine Hospital Affiliated to Zhejiang Chinese Medical University, Zhejiang Province, Huzhou 313000, China; 4.Medical College, Huzhou Teachers College, Zhejiang Province, Huzhou 313000, China
Abstract：Objective To investigate the effect of Danggui Buxue Decoction on patients with early lung cancer after resection. Methods By random number table method, a total of 94 patients with early lung cancer admitted to Huzhou Hospital of Traditional Chinese Medicine in Zhejiang Province from February 2021 to September 2022 were divided into experimental group and control group, with 47 cases in each group. All patients underwent partial pulmonary resection. The control group was given Pemetrexed combined with Cisplatin, and the experimental group was given angelica blood-supplementing decoction. The clinical efficacy, traditional Chinese medicine syndrome score, tumor marker level, and treatment safety of the two groups were compared. Results The clinical effect of the experimental group was better than that of the control group, and the difference was statistically significant (P＜0.05). After treatment, the scores of coughing hemoptysis, chest depression, fatigue, and tongue purpleness in the two groups were lower than before treatment, while those of the experimental group were lower than those of the control group, the differences were statistically significant (P＜0.05). After treatment, the levels of phosphatidylkinol 3-kinase, protein kinase, soluble tumor necrosis factor receptor in the two groups were lower than before treatment, while those of the experimental group were lower than those of the control group, and the differences were statistically significant (P＜0.05). There was no significant difference in the total incidence of adverse reactions (P＞0.05). Conclusion Angelica Buxue Decoction has good therapeutic effect on patients with early lung cancer after resection, can improve the symptoms of patients and reduce the level of tumor markers.
基金资助:浙江省中医药科学研究基金资助项R 2020B244)； 浙江省湖州市科学技术项K2021G Y 02)。
作者简介: 施胜钰（1980.9- ） ,男,副主任医师;研究方向:胸外科临床。
引用本文:
施胜钰1 王旭文1 赵良伟2 杜燕青1 江明3 刘重斌4. 当归补血汤对早期肺癌切除术后患者的影响[J]. 中国医药导报, 2023, 20(29): 112-115.
SHI Shengyu1 WANG Xuwen1 ZHAO Liangwei2 DU Yanqing1 JIANG Ming3 LIU Chongbin4. Effect of Angelica Buxue Decoction on patients with early lung cancer after resection. 中国医药导报, 2023, 20(29): 112-115.
[1] Kim M，Suh CH，Lee SM，et al. Diagnostic Yield of Staging Brain MRI in Patients with Newly Diagnosed Non-Small Cell Lung Cancer [J]. Radiology，2020，297（2）：419-427. [2] Yang CY，Yang JC，Yang PC. Precision Management of Advanced Non-Small Cell Lung Cancer [J]. Annu Rev Med，2020， 71：117-136. [3] 于海洋.比较单操作孔电视胸腔镜手术与开胸肺叶切除术对早期肺癌的治疗效果[J].中国现代药物应用，2020， 14（4）：41-43. [4] 王维新，何国丽，张剑锋，等.经肋间单孔胸腔镜肺叶切除术联合消癌平对非小细胞肺癌患者miR-210和miR-101表达的影响[J].中国药业，2023，32（5）：97-100. [5] 刘克元.顺铂联合长春瑞滨辅助化疗对行肺癌根治术后患者的临床疗效及毒副反应[J].中国医师杂志，2020，22（3）：428-431. [6] 焦丽静，李嘉旗，龚亚斌，等.中医药联合辅助化疗对早期非小细胞肺癌术后患者舌象变化规律的影响[J].上海中医药杂志，2020，28（2）：21-27. [7] 刘娜，王杰鹏，鲁辰希，等.当归补血汤对博莱霉素致肺纤维化大鼠PKD1/NF-κB/MnSOD信号通路的影响[J].中国实验方剂学杂志，2020，26（13）：66-72. [8] 杨龙海，叶波，魏星，等.最新国际肺癌TNM分期标准（第8版）修订稿解读[J].中国医刊，2016，51（9）：22-25. [9] Djaladat H，Bruins HM，Miranda G，et al. The association of preoperative serum albumin level and American Society of Anesthesiologists （ASA） score on early complications and survival of patients undergoing radical cystectomy for urothelial bladder cancer [J]. BJU Int，2014，113（6）：887-893. [10] 中华医学会，中华医学会肿瘤学分会，中华医学会杂志社.中华医学会肺癌临床诊疗指南（2018版）[J].中华肿瘤杂志，2018，40（12）：935-964. [11] 非小细胞肺癌辅助治疗胸外科共识专家组.非小细胞肺癌术后辅助治疗中国胸外科专家共识（2018版）[J].中国肺癌杂志，2018，21（10）：731-737. [12] 梁文杰，方朝义，沈莉，等.实验诊断学在现行《中医病证诊断疗效标准》中的应用分析[J].河北中医药学报，2011，26（2）：47-48. [13] Darras M，Ojanguren A，Forster C，et al. Short-term local control after VATS segmentectomy and lobectomy for solid NSCLC of less than 2 cm [J]. Thorac Cancer，2021，12（4）：453-461. [14] 高峰，刘徳军，张宪伟，等.老年广泛期小细胞肺癌EP/EC方案化疗的疗效与安全性分析[J].实用医学杂志，2020， 36（18）：2555-2558. [15] 张亦璐，焦丽静，许玲.中医药联合化疗治疗肺癌临床治疗模式进展[J].中华中医药杂志，2021，36（4）：2222- 2224. [16] 王娟，周明春.固本解毒汤联合化疗治疗非小细胞肺癌临床疗效观察[J].山西医药杂志，2021，50（22）：311-313. [17] 滕寅，冉鹏，金帮明，等.ILR2调控PI3K-AKT信号抑制MMP-2蛋白活性对非小细胞肺癌的影响[J].国际免疫学杂志，2022，45（3）：259-267. [18] 司海龙，陈玉，苟涛，等.培元抗癌汤通过PI3K-AKT- mTOR信号通路调节Lewis肺癌自噬抑制肿瘤生长和转移的实验研究[J].北京中医药大学学报，2021，44（8）：722-728. [19] 鲁辰希，王杰鹏，刘娜，等.当归补血汤对特发性肺纤维化大鼠血管新生因子HIF-1α和endostatin的影响[J].中华中医药杂志，2021，36（3）：1683-1687. [20] 肖旭阳，杜天宇，周玄，等 miR-184对顺铂耐药肺癌细胞PI3K、AKT和mTOR蛋白表达的影响[J].郑州大学学报（医学版），2022，57（3）：344-349. [21] 杜淑芳，苏智霞，樊肖冲，等. 苏芬太尼通过PI3K/Akt信号通路对肺癌A549细胞增殖、凋亡、迁移和侵袭的影响[J].中国实验诊断学，2021，25（3）：429-433. [22] 胡祥坤，潘春香，孙如坤，等. Akt、mTOR和PD-L1表达与肺癌临床病理特征的相关性[J].实用癌症杂志，2022， 37（4）：547-551. [23] Tan AC. Targeting the PI3K/Akt/mTOR pathway in non-small cell lung cancer （NSCLC） [J]. Thorac Cancer，2020，11（3）： 511-518. [24] Liu W，Lai H，Wang Z，et al. Does surgical margin affect recurrence and survival after sublobar pulmonary resection for lung cancer? [J]. Interact Cardiovasc Thorac Surg，2021， 28（6）：612-618. [25] 祝利民，史海霞，徐振晔.徐振晔教授中医药辨证论治大肠癌的临床数据挖掘[J].世界科学技术-中医药现代化，2021，23（6）：1773-1783.
2023, Vol. 20 
京公网安备 11010502046598号